Desarrollo de membrana epirretinal en pacientes con glaucoma que utilizan análogos de las prostaglandinas
Barra lateral del artículo
Contenido principal del artículo
##plugins.themes.bootstrap3.displayStats.downloads##
Detalles del artículo
Sección
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Cómo citar
Referencias
Joshi M, Agrawal S, Christoforidis JB. Inflammatory mechanisms of idiopathic epiretinal membrane formation. Mediators Inflamm. 2013; 2013:192582.
Knyazer B, Schachter O, Plakht Y, et al. Epiretinal membrane in diabetes mellitus patients screened by nonmydriatic fondo camera. Can J Ophthalmol. 2016; 51:41-6.
Miranda AF, Costa de Andrade G, et al. Outcomes after pars plana vitrectomy for epirretinal membranes associated with toxoplasmosis. Retina. 2016; 36:1713-7.
Fraser-Bell S, Guzowski M, Rochtchina E, et al. Five-year cumulative incidence and progression of epirretinal membranes: The Blue Mountains Eye Study. Ophthalmology. 2003; 110:34-40.
Sebag J. Anomalous posterior vitreous detachment: A unifying concept in vitreo-retinal disease. Graefes Arch Clin Exp Ophthalmol. 2004; 242:690-8.
Schumer RA, Camras CB, Mandahl AK. Putative side effects of prostaglandin analogs. Surv Ophthalmol. 2002; 47(Suppl 1):S219.
Varma R, Ying-Lai M, Francis BA, et al. Los Angeles Latino Eye Study Group. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: The Los Angeles Latino Eye Study. Ophthalmology. 2004; 111:1439-48.
Chu CJ, Johnston RL, Buscombe C, et al. United Kingdom Pseudophakic Macular Edema Study Group. Risk factors and incidence of macular edema after cataract surgery: A database study of 81984 eyes. Ophthalmology. 2016; 132:316-23.